AstraZeneca reports updated exploratory results from TOPAZ-1 Phase 3 trial

Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival, or OS, benefit at three years for patients with advanced biliary tract cancer, or BTC, AstraZeneca announced. At more than three years, results showed Imfinzi plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone. The median OS was 12.9 months for Imfinzi plus chemotherapy versus 11.3 months for chemotherapy alone. More than twice as many patients on the Imfinzi-based regimen were alive at three years versus chemotherapy alone. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “TOPAZ-1 raised the bar for the treatment of advanced biliary tract cancer, showing a remarkable survival benefit for Imfinzi added to chemotherapy with a well-tolerated regimen. These data represent the longest survival follow-up reported for immunotherapy in this setting, and the three-year landmark survival improvement underscores our commitment to improving long-term outcomes in gastrointestinal cancers.”